FDA staff say Replimune's melanoma trial failed to prove RP1 works

July 28, 2026 11:05 AM EDT PharmaFDA+ FDA staff say Replimune's piv­otal melanoma tri­al failed to prove RP1 works, push­ing down stock Max Bayer Senior Reporter FDA staff threw cold wa­ter on Replimune’s ad­vanced melanoma drug ahead of a crit­i­cal meet­ing with agency ad­vi­sors, writ­ing that the piv­otal study de­sign failed … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER